Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.10 -1.3%	$5.82	$4.35 ▼ $12.38	$310.66M	0.42	210,365 shs	158,942 shs
CMPX Compass Therapeutics	$2.38 +8.7%	$2.04	$0.77 ▼ $4.08	$302.84M	1.41	952,958 shs	765,396 shs
IVA Inventiva	$3.33 -2.9%	$3.44	$1.53 ▼ $4.05	$328.60M	0.75	64,433 shs	8,094 shs
PLRX Pliant Therapeutics	$1.31	$1.44	$1.10 ▼ $16.10	$80.42M	1.35	1.12 million shs	648,666 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	-1.29%	-7.99%	+3.04%	-17.79%	-13.48%
CMPX Compass Therapeutics	+8.68%	-2.06%	+12.80%	+6.25%	+112.50%
IVA Inventiva	-0.42%	-5.90%	+5.75%	+13.30%	+23.37%
PLRX Pliant Therapeutics	0.00%	-10.27%	-2.96%	-17.09%	-87.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.9779 of 5 stars	3.6	1.0	0.0	1.1	3.3	0.0
CMPX Compass Therapeutics	3.7074 of 5 stars	4.6	1.0	0.0	3.3	5.0	0.0
IVA Inventiva	1.661 of 5 stars	3.4	2.0	0.0	0.0	1.7	0.6
PLRX Pliant Therapeutics	4.2548 of 5 stars	3.0	4.0	4.7	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	260.66% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	451.47% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	212.22% Upside
PLRX Pliant Therapeutics	2.00	Hold	$13.31	916.22% Upside

Current Analyst Ratings Breakdown

Latest PLRX, CMPX, AURA, and IVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/21/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/4/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $24.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
4/2/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/2/2025	CMPX Compass Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $6.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CMPX Compass Therapeutics	$850K	387.18	N/A	N/A	$0.91 per share	2.62
IVA Inventiva	$9.95M	32.02	N/A	N/A	($1.21) per share	-2.75
PLRX Pliant Therapeutics	$1.58M	50.90	N/A	N/A	$5.00 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/8/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	-$210.30M	-$3.61	N/A	N/A	N/A	N/A	-67.56%	-52.54%	8/6/2025 (Estimated)

Latest PLRX, CMPX, AURA, and IVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
CMPX Compass Therapeutics	N/A	8.33	8.33
IVA Inventiva	N/A	0.92	0.92
PLRX Pliant Therapeutics	N/A	11.03	11.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
CMPX Compass Therapeutics	68.43%
IVA Inventiva	19.06%
PLRX Pliant Therapeutics	97.30%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
CMPX Compass Therapeutics	29.80%
IVA Inventiva	32.00%
PLRX Pliant Therapeutics	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
PLRX Pliant Therapeutics	90	61.39 million	56.48 million	Optionable

PLRX, CMPX, AURA, and IVA Headlines

Recent News About These Companies

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Hold" from Analysts

June 16 at 1:35 AM | marketbeat.com

Analysts Issue Forecasts for PLRX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Research Analysts Offer Predictions for PLRX FY2026 Earnings

June 10, 2025 | marketbeat.com

Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo

June 8, 2025 | msn.com

Bank of America Corp DE Has $1.59 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

June 5, 2025 | marketbeat.com

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by Analysts

May 24, 2025 | marketbeat.com

Pliant Therapeutics presents new fibrosis treatment data

May 23, 2025 | investing.com

Frazier Life Sciences Management L.P. Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

May 23, 2025 | marketbeat.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | finance.yahoo.com

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025 | globenewswire.com

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Pliant Therapeutics announces workforce reduction

May 3, 2025 | uk.investing.com

Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials

May 3, 2025 | nasdaq.com

Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value

May 2, 2025 | msn.com

Pliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical Trials

May 2, 2025 | biospace.com

Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes

May 2, 2025 | fiercebiotech.com

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX

April 25, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

April 24, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

April 23, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

April 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, CMPX, AURA, and IVA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.10 -0.08 (-1.29%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.10 +0.01 (+0.08%)

As of 06/18/2025 04:04 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$2.38 +0.19 (+8.68%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.43 +0.05 (+2.10%)

As of 06/18/2025 06:49 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Inventiva NASDAQ:IVA

$3.41 -0.02 (-0.61%)

As of 06/18/2025 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Pliant Therapeutics NASDAQ:PLRX

$1.31 0.00 (0.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.05 (+3.74%)

As of 06/18/2025 07:50 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time